Harbor Advisors LLC Has $249,000 Stake in Celgene Corporation (CELG)
Harbor Advisors LLC continued to hold its position in Celgene Corporation (NASDAQ:CELG) during the first quarter, Holdings Channel reports. The fund owned 2,000 shares of the biopharmaceutical company’s stock at the end of the first quarter. Harbor Advisors LLC’s holdings in Celgene Corporation were worth $249,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of Montreal Can increased its position in Celgene Corporation by 149.8% in the first quarter. Bank of Montreal Can now owns 3,299,988 shares of the biopharmaceutical company’s stock valued at $410,615,000 after buying an additional 1,979,061 shares in the last quarter. Investec Asset Management LTD purchased a new position in Celgene Corporation during the first quarter valued at about $194,490,000. State Street Corp increased its position in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Pioneer Investment Management Inc. increased its position in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after buying an additional 710,584 shares in the last quarter. Finally, Swiss National Bank increased its position in Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after buying an additional 588,000 shares in the last quarter. 78.41% of the stock is currently owned by hedge funds and other institutional investors.
Celgene Corporation (NASDAQ:CELG) traded up 0.18% during trading on Friday, reaching $130.61. The company’s stock had a trading volume of 2,735,623 shares. The stock’s 50-day moving average is $134.14 and its 200 day moving average is $124.30. The company has a market cap of $102.18 billion, a P/E ratio of 40.45 and a beta of 1.89. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00.
Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. Celgene Corporation’s revenue was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.44 EPS. On average, equities analysts forecast that Celgene Corporation will post $7.32 EPS for the current fiscal year.
WARNING: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/harbor-advisors-llc-has-249000-stake-in-celgene-corporation-celg/1479215.html.
Several research analysts have issued reports on CELG shares. Leerink Swann raised Celgene Corporation from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $98.00 price objective (up previously from $93.00) on shares of Celgene Corporation in a report on Wednesday, May 17th. William Blair reaffirmed an “outperform” rating on shares of Celgene Corporation in a report on Monday, June 26th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Finally, Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $147.00.
In related news, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. Insiders have sold a total of 235,255 shares of company stock worth $31,377,042 in the last ninety days. 0.95% of the stock is currently owned by insiders.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.